Spain’s POC manufacturing model reimagines CAR-T delivery
While the US relies on centralized, commercial CAR-T manufacturing, Spain is taking a different approach. At Hospital Clínic de Barcelona, point of care
Lymphoma
Multiple Myeloma
News
Leukemia
News
Pathways & Perspectives with Charles Craddock, CBE
Dr. Craddock talks life in general and about the past and future of blood cancer treatments.
Cellular Therapy
Lymphoma
News
Machine learning identifies inflammatory biomarker that predicts CAR-T response in lymphoma patients
Researchers have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR)
Multiple Myeloma
Dr. Lipof discusses Myeloma Action Month
In this video interview, Jodi Lipof, MD, explains why Myeloma Awareness Month matters more than ever.
Leukemia
Acute Myeloid Leukemia
News
No benefit to adding pevonedistat to SOC for patients with newly diagnosed AML
The addition of pevonedistat to azacitidine plus venetoclax failed to significantly improve response rates.
Lymphoma
Indolent B-Cell Lymphomas
Liso-cel favorable benefit over mosunetuzumab in 3rd-line R/R follicular lymphoma
Lisocabtagene maraleucel (liso-cel) was found to offer a favorable benefit–risk profile relative to mosunetuzumab as a third-line or later treatment for relapsed or refractory
Lymphoma
Indolent B-Cell Lymphomas
News
EC expands use of liso-cel CAR T-cell therapy for relapsed or refractory follicular lymphoma
The European Commission (EC) has granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of
Myelodysplastic Syndromes
EC approves imetelstat for transfusion-dependent anemia in lower-risk MDS
The European Commission (EC) has approved the marketing authorization for imetelstat (RYTELO), a first-in-class telomerase inhibitor, as a monotherapy for the treatment of
Lymphoma
T-Cell Lymphoma
Researchers document peripheral T-cell lymphomas across Latin America
A study documenting peripheral T-cell lymphoma epidemiology across Latin America found a high prevalence of adult T-cell leukemia or lymphoma and extranodal natural
Cellular Therapy
News
How do lifestyle factors play a role in the response to CAR-T therapy?
Ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models.